Next Article in Journal
Genome Instability Induced by Low Levels of Replicative DNA Polymerases in Yeast
Next Article in Special Issue
TALEN-Mediated Gene Targeting for Cystic Fibrosis-Gene Therapy
Previous Article in Journal
Versatility of Synthetic tRNAs in Genetic Code Expansion
Review

Cystic Fibrosis Gene Therapy: Looking Back, Looking Forward

Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA
*
Author to whom correspondence should be addressed.
Genes 2018, 9(11), 538; https://doi.org/10.3390/genes9110538
Received: 27 September 2018 / Revised: 30 October 2018 / Accepted: 31 October 2018 / Published: 7 November 2018
(This article belongs to the Special Issue Cystic Fibrosis: Therapy and Genetics)
Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that encodes a cAMP-regulated anion channel. Although CF is a multi-organ system disease, most people with CF die of progressive lung disease that begins early in childhood and is characterized by chronic bacterial infection and inflammation. Nearly 90% of people with CF have at least one copy of the ΔF508 mutation, but there are hundreds of CFTR mutations that result in a range of disease severities. A CFTR gene replacement approach would be efficacious regardless of the disease-causing mutation. After the discovery of the CFTR gene in 1989, the in vitro proof-of-concept for gene therapy for CF was quickly established in 1990. In 1993, the first of many gene therapy clinical trials attempted to rescue the CF defect in airway epithelia. Despite the initial enthusiasm, there is still no FDA-approved gene therapy for CF. Here we discuss the history of CF gene therapy, from the discovery of the CFTR gene to current state-of-the-art gene delivery vector designs. While implementation of CF gene therapy has proven more challenging than initially envisioned; thanks to continued innovation, it may yet become a reality. View Full-Text
Keywords: history; viral vectors; animal models; clinical trials; adeno-associated virus; adenovirus; lentivirus; retrovirus; non-viral vectors history; viral vectors; animal models; clinical trials; adeno-associated virus; adenovirus; lentivirus; retrovirus; non-viral vectors
Show Figures

Figure 1

MDPI and ACS Style

Cooney, A.L.; McCray, P.B., Jr.; Sinn, P.L. Cystic Fibrosis Gene Therapy: Looking Back, Looking Forward. Genes 2018, 9, 538. https://doi.org/10.3390/genes9110538

AMA Style

Cooney AL, McCray PB Jr., Sinn PL. Cystic Fibrosis Gene Therapy: Looking Back, Looking Forward. Genes. 2018; 9(11):538. https://doi.org/10.3390/genes9110538

Chicago/Turabian Style

Cooney, Ashley L.; McCray, Paul B., Jr.; Sinn, Patrick L. 2018. "Cystic Fibrosis Gene Therapy: Looking Back, Looking Forward" Genes 9, no. 11: 538. https://doi.org/10.3390/genes9110538

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop